Contineum Therapeutics (CTNM) CSO sells shares via 10b5-1 stock plan

Rhea-AI Filing Summary

Contineum Therapeutics Chief Scientific Officer Lorrain Daniel S. reported planned stock sales under a prearranged Rule 10b5-1 trading plan. On February 3, 2026, the insider sold 3,000 shares of Class A common stock at a weighted average price of $14.8229 and 1,170 shares at a weighted average price of $15.2451. The prices in each trade reflect multiple executions within disclosed ranges. After these transactions, the officer directly held 156,052 shares of Class A common stock and had an additional 6,842 shares reported as indirectly owned by a spouse.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Lorrain Daniel S.

(Last) (First) (Middle)

3565 GENERAL ATOMICS COURT, SUITE 200

(Street)

SAN DIEGO CA 92121

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Contineum Therapeutics, Inc. [ CTNM ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Scientific Officer

3. Date of Earliest Transaction (Month/Day/Year)
02/03/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Class A Common Stock	02/03/2026		S(1)		3,000	D	$14.8229(2)	157,222	D
Class A Common Stock	02/03/2026		S(1)		1,170	D	$15.2451(3)	156,052	D
Class A Common Stock								6,842	I	By Spouse

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. These transactions were effected pursuant to a 10b5-1 trading plan adopted by the reporting person on September 23, 2025.

2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $14.12 to $15.08, inclusive. The reporting person undertakes to provide to Issuer, any security holder of Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4.

3. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $15.12 to $15.45, inclusive. The reporting person undertakes to provide to Issuer, any security holder of Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4.

	/s/ Peter Slover, Attorney-in-Fact	02/05/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did CTNM’s Chief Scientific Officer report?

The Chief Scientific Officer of Contineum Therapeutics (CTNM) reported selling Class A common stock on February 3, 2026. Two separate sales totaled 4,170 shares, executed under a prearranged Rule 10b5-1 trading plan adopted on September 23, 2025.

How many CTNM shares did the insider sell and at what prices?

The insider sold 3,000 shares at a weighted average price of $14.8229 and 1,170 shares at a weighted average price of $15.2451. Each weighted price reflects multiple trades within specified price ranges disclosed in the filing footnotes.

How many CTNM shares does the insider hold after these transactions?

Following the reported sales, the Chief Scientific Officer directly held 156,052 shares of Contineum Therapeutics Class A common stock. The filing also reports an additional 6,842 shares as indirectly owned through the insider’s spouse, reflecting separate beneficial ownership.

Were the CTNM insider stock sales made under a 10b5-1 trading plan?

Yes. The filing states the transactions were effected under a Rule 10b5-1 trading plan adopted by the reporting person on September 23, 2025. Such plans allow prearranged trading according to preset instructions, independent of later day-to-day market decisions.

What price ranges applied to the CTNM insider stock sales?

For the 3,000-share sale, individual trades occurred between $14.12 and $15.08. For the 1,170-share sale, trades occurred between $15.12 and $15.45. Each transaction’s reported price is a weighted average across those multiple executions.

Does the CTNM insider Form 4 mention indirect ownership through a spouse?

Yes. The filing lists 6,842 shares of Class A common stock as indirectly owned, labeled “By Spouse.” This indicates separate beneficial ownership reported for compliance, in addition to the insider’s directly held 156,052 shares after the reported sales.